Parkinson Disease, Secondary
"Parkinson Disease, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
Descriptor ID |
D010302
|
MeSH Number(s) |
C10.228.140.079.862.800 C10.228.662.600.700
|
Concept/Terms |
Parkinson Disease, Secondary- Parkinson Disease, Secondary
- Secondary Parkinson Disease
- Symptomatic Parkinson Disease
- Parkinsonism, Symptomatic
- Symptomatic Parkinsonism
- Secondary Parkinsonism
- Parkinson Disease, Symptomatic
- Parkinsonism, Secondary
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease, Secondary".
This graph shows the total number of publications written about "Parkinson Disease, Secondary" by people in this website by year, and whether "Parkinson Disease, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2013 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2021 | 1 | 1 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parkinson Disease, Secondary" by people in Profiles.
-
Drug-induced parkinsonism: diagnosis and treatment. Expert Opin Drug Saf. 2024 Dec; 23(12):1503-1513.
-
Novel case of Parkinson's disease and schizophrenia: challenges in the management. BMJ Case Rep. 2021 Jul 29; 14(7).
-
Cycad Genotoxin Methylazoxymethanol Disrupts the Brain Ubiquitin-Proteasome Pathway, Tau and a-Synuclein, as Reported in ALS-PDC. J Neuropathol Exp Neurol. 2021 02 22; 80(3):286-288.
-
Purkinje cell misfiring generates high-amplitude action tremors that are corrected by cerebellar deep brain stimulation. Elife. 2020 03 17; 9.
-
The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem. 2013 Jul 26; 288(30):21955-71.
-
Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014 Jan; 17(1):104-6.
-
F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013 Jan; 70(1):20-4.
-
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011 May 06; 286(18):16504-15.
-
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010 Oct; 115(1):188-99.
-
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Res Bull. 2009 Feb 16; 78(2-3):91-6.